Option chain shows key data for Wuxi AppTec Co's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Wuxi AppTec Co.

Wuxi AppTec Co (OTC:WUXAY) Stock, Option Chain

Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by China, Europe, and other regions.

Trump Orders Crackdown On Chinese Investments In Key Sectors Including Technology Citing 'National Security' Concern

News

Politics

Markets

PHBBF

WUXAY

WXXWY

President Donald Trump has issued a stringent warning to pharmaceutical companies, advising them to repatriate their manufacturing to the US or face the possibility of tariffs.

Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs

Biotech

Penny Stocks

General

HOTH

Photo by Julia Koblitz on Unsplash

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Hoth Therapeutics Reports Being Ready For 2022 As It Anticipates Major Milestones In Drug Pipeline

WUXI APPTEC CO UNSP/ADR by Wuxi Apptec Co Ltd.

Wuxi AppTec Co Ltd

Earnings

Press Releases

Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ

Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY

WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year

Commodities

WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment

WuXi AppTec's Couvet Site Receives EcoVadis 2024 Silver Medal Rating

WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating

WuXi AppTec's Commitment to Sustainability Recognized by the Dow Jones Sustainability Indices (DJSI) for the Fourth Consecutive Year

WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)

WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs

WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections

Wuxi AppTec Co

Comments

Wuxi AppTec Co

Wuxi AppTec Co (WUXAY) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell